Type-2 diabetes mellitus (T2DM) results in reduced insulin secretion and there is a need for a proactive, multifactorial approach to manage T2DM. Combinations of oral antidiabetic drugs (OADs) are accepted as second line treatment step or as dual and triple combination therapy. Exogenous Insulin therapy deals only with secretory component of the pathophysiology of T2DM. Glucagon-like peptide-1receptor agonists repress the secretion and decrease the prandial glucose excursions. Positive result of the combination of GLP-1-RA and insulin was confirmed by several retrospective studies and proves for the different techniques are also discussed in this chapter. Effect on insulin dose, effect on body weight and effects on lipids and cardiovascular risk are discussed in this chapter. Hypoglycemia is found to be an unlikely adverse event when GLP-1-RAs are used alone. Unanswered issues regarding combination therapy should be discussed since they have great deal of promise in the future.